Athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies.
The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. Our business includes medical technology innovation centers and a unique manufacturing supply chain across both China and North America. Through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.
The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. Our business includes medical technology innovation centers and a unique manufacturing supply chain across both China and North America. Through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.
Location: United States, New York, Buffalo
Employees: 201-500
Founded date: 2003
Investors 3
Mentions in press and media 25
| Date | Title | Description |
| 29.09.2025 | Hanmi's Oral Delivery Platform Compound Licensed to Gilead | Hanmi and HHP will grant Gilead an exclusive license to Encequidar and provide access to drug supply. SEOUL, South Korea, Sept. 29, 2025 /PRNewswire/ -- Hanmi Pharm announced on September 29 that it has entered into a global licensing and c... |
| 08.07.2024 | CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP | BEIJING, July 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products today announces a... |
| 11.07.2022 | Struggling biotech sells its API manufacturing arm to narrow its focus | After a stock plunge in 2021 following a key FDA rejection, cancer biotech Athenex crashed into penny stock territory this year and is now looking to sell a piece of itself to make some cash. The company has agreed to sell of... |
| 09.02.2022 | Athenex to Present at the 11th Annual SVB Leerink Global Healthcare Conference | BUFFALO, N.Y., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related con... |
| 12.01.2022 | Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility | BUFFALO, N.Y., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related con... |
| 12.01.2022 | Athenex : Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility - Form 8-K | Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility Buffalo, N.Y., JANUARY 12, 2022 (GLOBE NEWSWIRE) - Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, developme... |
| 29.11.2021 | Athenex Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review | BUFFALO, N.Y., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related con... |
| 22.11.2021 | Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer at SABCS 2021 | Analysis of safety data demonstrated that patients with elevated liver tests were at increased risk of neutropenia related toxicities Post hoc analysis of this subgroup of patients with hepatic impairment was conducted and showed a median s... |
| 18.11.2021 | Athenex to Present at the Evercore ISI 4th Annual HealthCONx Conference | BUFFALO, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related con... |
| 04.11.2021 | Athenex Provides Third Quarter 2021 Corporate and Financial Update | Held FDA Type A Meeting for oral paclitaxel in metastatic breast cancer Klisyri® launched in Europe ANCHOR Phase 1 interim results accepted for poster presentation at 2021 ASH 3Q product sales were $27.0M, up 9% year-over-year Company now e... |
Show more